Articles By Anuja Singh
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung…
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
By
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Can AI-Powered Platforms from Certara, Recursion, and Charles River Cut Drug Development Timelines by…
Key Takeaways FDA’s New Roadmap Sparks Industry Transformation The U.S. FDA has outlined a bold strategy to make…
Will Bayer’s Backing of RedHill’s Opaganib Open New Avenues in Precision Oncology?
Key Takeaways Bayer-Supported Trial Expands Opaganib’s Potential RedHill Biopharma’s collaboration with Bayer has taken center stage with the…
Could Merck’s Oral PCSK9 Inhibitor Enlicitide Transform Cholesterol Management?
Key Takeaways Breakthrough in Cardiovascular Innovation Merck announced positive topline Phase 3 results for enlicitide decanoate, its investigational…
Could Johnson & Johnson’s 99.7% Acute Success in VARIPURE Substudy Redefine the Global Pulsed…
Key Highlights Breakthrough Clinical Data from ESC 2025Johnson & Johnson MedTech unveiled results from the VARIPURE substudy of…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung…
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Can AI-Powered Platforms from Certara, Recursion, and Charles River Cut Drug Development Timelines by…
Key Takeaways FDA’s New Roadmap Sparks Industry Transformation The U.S. FDA has outlined a bold strategy to make…
Will Bayer’s Backing of RedHill’s Opaganib Open New Avenues in Precision Oncology?
Key Takeaways Bayer-Supported Trial Expands Opaganib’s Potential RedHill Biopharma’s collaboration with Bayer has taken center stage with the…
Could Merck’s Oral PCSK9 Inhibitor Enlicitide Transform Cholesterol Management?
Key Takeaways Breakthrough in Cardiovascular Innovation Merck announced positive topline Phase 3 results for enlicitide decanoate, its investigational…
Could Johnson & Johnson’s 99.7% Acute Success in VARIPURE Substudy Redefine the Global Pulsed…
Key Highlights Breakthrough Clinical Data from ESC 2025Johnson & Johnson MedTech unveiled results from the VARIPURE substudy of…